Identität

Afoxolaner Impurity 17

Nicht angegeben · C23H16Cl2F3N3O3

01Identität

Lazychem IDLC-34566
CAS RNNicht angegeben
PubChem CID137023203
Molecular formulaC23H16Cl2F3N3O3
Molecular weight510.3 g/mol
IUPAC name4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-N-(methoxyiminomethyl)naphthalene-1-carboxamide
InChIKeyQXJSNLSZRYVAOY-UHFFFAOYSA-N

02Struktur und Stereochemie

Two-dimensional chemical structure of Afoxolaner Impurity 17
Two-dimensional structure for the PubChem identity linked to this record. Confirm the identifiers before analytical use.

The parsed structure contains 4 rings, includes aromatic atoms, includes aliphatic carbon, contains at least one halogen atom. These statements are calculated from the published structure string.

Defined stereocentres0
Ring count4
Secondary amines0
Tertiary amines0
SMILESCON=CNC(=O)C1=CC=C(C2=CC=CC=C21)C3=NOC(C3)(C4=CC(=CC(=C4)Cl)Cl)C(F)(F)F
InChINicht angegeben

03Stereochemistry

The published structure contains 0 defined and 1 unassigned tetrahedral stereocentre. The exact wedge and dash depiction is shown above.

Defined centres0Structure assigned
Unassigned centres1Structure unspecified
Assignment statusUnassignedExact published identity
Tetrahedral upper bound≤ 2Before symmetry reduction

Published same-connectivity configurations

1 record

These records have the same connectivity, molecular formula and protonation layer, but a different complete InChIKey stereochemical layer. Only separately structure-linked records are shown.

No additional structure-linked configuration with the same connectivity is currently present in the LazyChem dataset.

Scope: The mathematical 2^n value is only an upper bound. Symmetry and other stereogenic elements can change the number of distinct stereoisomers. A hypothetical configuration is not published as a compound record without a verified structure identity.

04Status in Indien

Exact-compound status is evaluated only against the published name and CAS number. Confirm the current official instrument before a regulatory decision.

05Namen und Beziehungen

API und Ausgangsarzneistoff

Nicht angegeben

Namen und Beziehungen

    06Quellen